19 December 2017
: Case report
A Case of Osteonecrosis of the Jaw in a Patient with Crohn’s Disease Treated with Infliximab
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Unusual setting of medical care, Unexpected drug reaction
Gianfranco Favia1AD, Angela Tempesta- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- *Corresponding author: [email protected]
- B Data collection/entry
- E Preparation of manuscript
- F Literature analysis/search
- E Preparation of manuscript
- F Literature analysis/search
- A Study design/planning
- D Data interpretation
- A Study design/planning
- D Data interpretation
- A Study design/planning
- C Data analysis/statistics
- D Data interpretation
- F Literature analysis/search
DOI: 10.12659/AJCR.905355
Am J Case Rep 2017; 18:1351-1356
Abstract
BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, occurring in patients undergoing treatments with antiresorptive or antiangiogenic agents, such as bisphosphonates, denosumab, or bevacizumab, for different oncologic and non-oncologic diseases. The aim of this study was to report a case of MRONJ in a patient taking infliximab, an anti-TNF-𝛼 antibody used to treat Crohn’s disease, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
CASE REPORT: A 49-year-old female patient affected by Crohn’s disease, who had been undergoing 250 mg intravenous infliximab every six weeks for 12 years, with no history of antiresorptive or antiangiogenic agent administration, came to our attention for post-surgical MRONJ, associated with a wide cutaneous necrotic area of her anterior mandible. Following antibiotic cycles, the patient underwent surgical treatment with wide bone resection and debridement of necrotic tissues; after prolonged follow-up (16 months), the patient completely healed without signs of recurrence.
CONCLUSIONS: Prevention of MRONJ by dental check-up before and during treatments with antiresorptive treatments (bisphosphonates or denosumab) is a well-established procedure. Although further studies are required to confirm the role of infliximab in MRONJ, based on the results of this study, we propose that patients who are going to be treated with infliximab should also undergo dental check-up before starting therapy, to possibly avoid MRONJ onset.
Keywords: Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Crohn Disease
1411 17
In Press
25 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939239
24 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939520
24 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939697
23 May 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939642
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347